GlassScriptPhysician profile
Suzanne Yaws
NPI 1679136394
$25,039.68
in general payments reported to CMS, 2019-2025
26 companies · $5,687 in 2025
The $5,687 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,103 · 2022: $4,479 · 2023: $6,084 · 2024: $5,686 · 2025: $5,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,318.75 |
| Education | $138.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $4,813.75 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $3,860.79 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $2,593.29 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $2,306.21 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Abbvie INC. | $2,094.34 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,799.85 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,576.75 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Axsome Therapeutics, INC. | $1,441.27 | 2022-2025 | Auvelity |
| Lundbeck LLC | $1,376.89 | 2021-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $959.40 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $390.41 | 2021-2023 | Trintellix |
| Avanir Pharmaceuticals, INC. | $378.78 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $376.38 | 2021-2024 | Nuplazid |
| Eisai INC. | $175.20 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $173.24 | 2024-2025 | Fanapt |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $125.00 | 2021 | |
| Ironshore Pharmaceuticals INC. | $116.94 | 2022-2023 | Jornay Pm |
| Amgen INC. | $113.29 | 2021 | |
| Janssen Scientific Affairs, LLC | $78.88 | 2024 | Invega Sustenna |
| Corium, LLC | $74.51 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $67.74 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.32 | 2021 | |
| Tris Pharma INC | $49.55 | 2023-2024 | Dyanavel Xr |
| Indivior INC. | $19.59 | 2024 | Perseris |
| Alfasigma USA, INC. | $15.23 | 2022 | |
| Sunovion Pharmaceuticals INC. | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Yaws listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.